Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)

Table 3 Calculation of dose reduction for FTD/TPI in mg according to BSA used in the TRITICC trial

Starting dose 20 mg/m²	BSA (m²)	Dose in mg 2 × daily	Tablets per dose		Total daily dose (mg)
Starting dose 20 mg/m²	BSA (m²)	Dose in mg 2 × daily	15 mg	20 mg	Total daily dose (mg)
	< 1.14	20	0	1	40
	1.15 – 1.34	25!	2!	1!	50!
	1.35 – 1.59	30	2	0	60
	1.60 – 1.94	35	1	1	70
	1.95 – 2.09	40	0	2	80
	2.10 – 2.34	45	3	0	90
	> 2.35	50	2	1	100

(!) At a total daily dose of 50 mg, patients should take 1 × 20 mg tablet in the morning and 2 × 15 mg tablets in the evening

ISSN: 1471-2407